Genome-wide approaches to non-invasive screening and characterization of ovarian cancers

PROJECT SUMMARY

Ovarian cancer is the deadliest gynecological cancer, in part because there is no widely used screening test and 80% of

tumors are diagnosed at a late stage. Though ovarian cancer screening has the poten>al to diagnose tumors at early

stages when pa>ent outcomes are far be?er (90% survival for stage I cancer vs. ve results leading to unnecessary procedures in a disease with low popula>on

prevalence, (2) Achieving high enough sensi>vity to be a clinically useful test, and (3) Ensuring accessibility and pa>ent

compliance with screening. Much of my early PhD work, and work in my mentor’s lab, has pioneered high performance

blood tests that use cell-free DNA fragmenta>on pa?erns to detect cancer. These fragmentomic assays can detect subtle

changes to DNA shed from tumor cells even using low-coverage sequencing of ents. Given the cri7cal clinical need, the overarching goal of my

work is to advance our understanding of ovarian tumorigenesis and develop an accessible, high-performance liquid

biopsy for ovarian cancer screening. A limita>on of current liquid biopsies is that they don’t incorporate informa>on

from the ~50% of the genome comprising repeat elements, which have long been implicated in carcinogenesis but have

been difficult to study due to incomplete genome references and technical genome alignment challenges. In preliminary

work, I show a novel approach I developed that allows the study of repeat landscapes in short-read sequencing and that

has iden>fied over 800 new elements not previously implicated in cancer. The ability to use this approach in short-read

sequencing opens the door to studying repeat landscapes in cell-free DNA, where most fragments are 150-180bp in

length. I propose three specific aims: In Aim 1, I will expand this approach to develop novel bioinforma>cs approaches

enabling the study of repeat elements in cell-free DNA. In Aim 2, I will develop and test sensi>ve and specific cell-free

DNA liquid biopsies for ovarian cancer. In Aim 3, I will characterize genomic changes to repeat elements during ovarian

tumorigenesis, from normal >ssue to pre-cancerous lesion to tumor. Successful execu7on of these aims has the

poten7al to advance our understanding of the role of the so-called “dark genome” in ovarian tumorigenesis, change

the paradigm for liquid biopsies by illumina7ng cancer-related changes to repeat elements, and apply these

discoveries to a screening technology for ovarian cancer. This work may also serve as a basis for future pan-cancer

screening methods. The proposed work will provide me with outstanding mentorship and scien>fic training in basic and

transla>onal science and help me advance my career as a future physician-scien>st and independent inves>gator.